Long‐term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia
Young‐Mock Lee(University of Connecticut), David A. Weinstein(University of Connecticut), Andrew J. Specht(Japan Small Animal Medical Center), Ana Estrella(University of Connecticut), Kathryn Dahlberg(Connecticut Children's Medical Center), Kirsten E. Coleman(University of Florida), Thomas J. Conlon(Adelson Foundation), Laurie M. Brown(University of Florida), Monika Dambska(University of Florida)
Cited by 27
Related Papers
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
|Proceedings of the National Academy of Sciences|2009|322